Online Program Home
My Program

Abstract Details

Activity Number: 639
Type: Topic Contributed
Date/Time: Thursday, August 4, 2016 : 8:30 AM to 10:20 AM
Sponsor: Biopharmaceutical Section
Abstract #318874 View Presentation
Title: Practical Considerations for the Implementation of the Modified Toxicity Probability Interval (MTPI) Design and Associated Change Management
Author(s): Erik Pulkstenis*
Companies: MedImmune
Keywords: dose escalation ; oncology ; innovation ; mTPI
Abstract:

The mTPI design (Ji 2010) has increased in use due to an awareness that it is more reliable than 3+3 at selecting the true MTD, and that it has been shown to be safer (Ji and Wang 2013). However, many practical issues remain to be addressed. These include how to determine sample size and additional escalation conditions that may be desired. Fixing the sample size is a challenge and given that mTPI prefers to enroll at the current MTD (like CRM), it may not push the dose when additional gains in efficacy may be made in the presence of a flatter dose-toxicity curve. In some cases 'capping' dose levels at a maximum sample size as well as changing specific cells of the mTPI design may be desirable. In addition, operating characteristics of the design may depend on whether empirical estimates of toxicity are used vs. posterior estimates for both dose escalation decisions as well as MTD determination. This presentation will address some of these issues. Importantly the operating characteristics of mTPI under some of the additional constraints will be assessed. In addition, change management aspects of moving from 3+3 to mTPI within an organization will be discussed.


Authors who are presenting talks have a * after their name.

Back to the full JSM 2016 program

 
 
Copyright © American Statistical Association